TDOC - Teladoc Health, Inc.
68.44 0.00 (0.00%)
After hours: 6:08PM EDT
| Previous Close | 69.20 |
| Open | 68.80 |
| Bid | 68.10 x 800 |
| Ask | 68.64 x 900 |
| Day's Range | 68.00 - 69.47 |
| 52 Week Range | 42.08 - 89.05 |
| Volume | 937,063 |
| Avg. Volume | 1,263,735 |
| Market Cap | 4.9B |
| Beta (3Y Monthly) | 1.88 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.52 |
| Earnings Date | Jul 31, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 79.58 |
- Kiplinger•6 hours ago
Analysts' 7 Top Stock Picks for 2019's Second Half
Stocks are sitting atop the clouds. All three major indexes have recently surged to surged to all-time highs amid strong signals that the Federal Reserve will cut interest rates soon. Standard & Poor's 500-stock index just closed above 3,000 for the first time. The Dow Jones Industrial Average recently made its first finish above the 27,000 mark.But the question of whether the markets can maintain these lofty heights is something you should seriously consider when making stock picks over the next few weeks.Consider this: More than three-quarters of S&P; 500 companies have issued negative earnings per share (EPS) guidance for the second quarter thanks to trade uncertainty and lingering concerns about global growth. (Those earnings reports will be rolling out over the next couple months.) And while Wall Street is absolutely pricing in an interest-rate cut, no one yet knows for sure whether the Fed will cut, and how deeply it will cut if it does.So tread carefully in the second half. The key is to find stocks that are not just primed to continue outperforming, but also less vulnerable to slumping along with a broader-market pullback. One way to do this is to seek out stocks with a strong Street sentiment. TipRanks tracks more than 5,200 analysts and compiles their ratings to deliver a picture of just how optimistic (or pessimistic) the pros are about most companies you can invest in.These are the seven top stock picks for the second half, according to analyst ratings doled out over the past three months. SEE ALSO: 25 Stocks Every Retiree Should Own
- Motley Fool•3 days ago
2 Companies Trying to Change U.S. Healthcare
Though it's no small task, here are two companies that are trying to change the way Americans think about their healthcare.
- Motley Fool•6 days ago
McDonald’s Franchisees: Give Us the Bird
The people have spoken: McDonald’s should really put some more chicken on the menu.
- Motley Fool•6 days ago
McDonald's Franchisees Want a Sandwich That Can Compete With Chick-fil-A Chicken
The people have spoken: McDonald’s should really put some more chicken on the menu.
- GlobeNewswire•6 days ago
Teladoc Health to Announce Second-Quarter 2019 Financial Results
PURCHASE, NY, July 12, 2019 -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, announced today that it will release second-quarter 2019 results on.
- PR Newswire•8 days ago
MinuteClinic Launches Virtual Visit Offering in 8 Additional States
WOONSOCKET, R.I., July 10, 2019 /PRNewswire/ -- CVS Health (CVS) today announced that MinuteClinic, the company's retail medical clinic, has rolled out its virtual visit offering in eight additional states. People with minor illnesses and injuries, skin conditions and other wellness needs can now seek care through MinuteClinic Video Visits, a telehealth offering, in the states of Arkansas, Connecticut, Hawaii, Indiana, Minnesota, Missouri, Oklahoma and Texas. MinuteClinic Video Visits provide patients with access to care 24 hours a day, seven days a week from their mobile device or computer.
- TipRanks•14 days ago
3 Healthcare Stocks Ready to Grow
2019 has been a rocky year for the healthcare industry. The general healthcare market sell-off combined with criticism over high costs poses a cause for concern. Despite the lackluster performance of many healthcare stocks so far in 2019, there are a few standouts with long-term growth potential. Using data from TipRanks, we’ve narrowed down three stocks in the healthcare space that analysts believe are well positioned for future growth. Boston Scientific Corporation (BSX)Unlike other stocks in the healthcare industry, Boston Scientific shares saw significant growth over the last year. The medical equipment manufacturer’s stock increased 22.5% while the industry as a whole saw only a 4% increase. In the quarter ending March 31, the company reported calendar year increases in revenue and net profit. Revenue was up from $2.38 billion to $2.49 billion while net profit increased from $298 million to $424 million.Boston Scientific’s long-term growth plan, which includes projections of double digit adjusted EPS growth through 2020, gives analysts reason to believe the company will continue to outperform. Raj Denhoy, a top analyst from Jeffries, raised his price target from $44 to $48 stating that the company’s projections from their investor meeting were “another positive look at a story that has been in sharp ascendancy for the last five years.” He added that the projections are even somewhat conservative given the company’s stability and the addition of new products in the next few quarters. Another five-star analyst, Matt Miksi of Credit Suisse, explained that he is unsurprised by Boston’s success when discussing the company’s sale of various products from their portfolio to Varian for $90 million. He maintained the stock’s Outperform rating and $45.00 price target, indicating a 5.56% upside. The Street’s outlook on the stock is bullish, with 10 analysts from TipRanks giving a buy rating vs just 1 hold over the last three months. The stock boasts a ‘Strong Buy’ analyst consensus and an average price target of $45.63, suggesting a 7.04% upside. View BSX Price Target & Analyst Rating Details Invitae Corporation (NVTA)Invitae is an innovative biotech company in the genetic testing segment of the market whose goal is to make genetic screenings more affordable and accessible. Five-star financial blogger, Todd Campbell, notes that the company cut the cost of goods sold by upwards of 20% over the last year as well as reported year-over-year sales of $148 million, a 117% increase. Management is projecting sales of $220 million in 2019 and a test volume of 500,000. Additionally, the company announced on June 17 that they are set to acquire Singular Bio. “The acquisition of Singular Bio gives Invitae a critical technology that can turn the NIPS business into a 50% gross margin performer once fully integrated into the firm’s process, and if you broke out Invitae's cancer business, it turned a profit as a standalone business as of Q1 of this year,” stated Sean George, the company’s CEO. Five-star rated Cowen & Co. analyst, Doug Schenkel, is confident in the stocks ability to grow, reiterating his Outperform rating and $30.00 price target. He believes Singular Bio’s “flexible, quick, and less expensive technology will give Invitae a competitive advantage over other companies with sequencing-based and microarray-based approaches for some applications including NIPS/NIPT.”The consensus among analysts is that the stock is a ‘Strong Buy’, with an average price target of $30.00, suggesting a 23.61% upside. View NVTA Price Target & Analyst Rating Details Teladoc Health, Inc. (TDOC)The last stock on our list doesn’t appear to be slowing down any time soon. Teladoc meets the growing demand for healthcare access in a cost-effective way by providing virtual medical care through telephone and videoconferencing technology. Share prices surged by 35.73% year-to-date. Management is confident that this growth will continue throughout the rest of the year. Based on Teladoc’s recent acquisitions as well as their competitive advantage within this segment of the healthcare sector, management is anticipating 37% revenue growth. In the most recent quarter, the company reported 29% organic growth with 1,063,000 total visits. Richard Close, an analyst at Canaccord Genuity, believes that the telemedicine company’s “penetration into its existing client base will allow it to generate robust organic growth.” He maintains his buy rating on the stock and price target of $95.00 (41.20% upside). Five-star Piper Jaffray analyst, Sean Wieland, remains bullish on the stock. He explained that he views the completion of their CFO search and an impending United deal as “two important catalysts and remains a buyer of the stock in front of them.” He reiterated his Overweight rating and price target of $86.00, suggesting a 27.82% upside.While the on-demand remote medical care provider isn’t profitable yet, analysts believe in Teladoc’s growth potential. The stock has a ‘Strong Buy’ analyst consensus, with 12 out of 13 analysts on TipRanks giving a buy rating. The average price target of $79.83 shows that analysts believe the stock price could increase by 18.65%. View TDOC Price Target & Analyst Rating DetailsFind your own best investment with TipRanks’ Analysts’ Top Stocks page.
- InvestorPlace•16 days ago
Best Stocks for 2019: Teladoc Stock Is Here to Stay
Editor's note: This column is part of our Best Stocks for 2019 contest. Jason Moser's pick for the contest is Teladoc Health (NYSE:TDOC).Teladoc looked like it was going to end the quarter in fourth or even fifth place. But after a rally that started last Wednesday, TDOC stock slid past Adobe (NASDAQ:ADBE), Amazon (NASDAQ:AMZN) and Charlotte's Web (OTCMKTS:CWBHF) for a second-place finish.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSo how does TDOC look going forward? TDOC's First Quarter EarningsTeladoc's first quarter was a good one. Revenue of $128.6 million marked growth of 43% (23% organic) and total U.S. paid members are now at 26.7 million along with 10.2 million visit fee-only users. Total visits of 1,063,000 represented 29% organic growth.It's also worth noting that this represented the first quarter where the business crossed 1 million doctor's visits, and that was actually in spite of a weaker flu season. International visits grew from basically nothing a year ago to 282,000 this quarter.Gross margin was 65.3% versus 70% a year ago and as we've seen in previous quarters this investment in behavioral along with a more comprehensive offering. TDOC's balance sheet remains in good shape considering the deals the company has made recently with $479 million in cash and equivalents and $450 million debt. It's also worth noting that debt is in convertible notes that don't even come due until 2022 and 2025. Looking Ahead for TDOCThe business is still unprofitable but what else is new? Profitability will come in time and management reiterates that the company will be cash flow positive for the first time in 2019 so we'll hold them to that target. * 7 Restaurant Stocks to Put on Your Plate The CVS and Aetna relationships have never been stronger and we should expect some additional news regarding Teladoc and Aetna at some point in the near future as well.CEO Jason Gorevic likes this business because there are so many levers for growth. I tend to agree; healthcare is a phenomenally large global market opportunity.One final note, the CFO search is over as Mala Murthy has joined the Teladoc team. A seasoned vet, Murthy comes to the company from American Express so it's encouraging to see the team in a good place going forward.As of this writing, Jason Moser, a senior analyst with The Motley Fool, held shares of TDOC. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 F-Rated Stocks to Sell for Summer * 7 Stocks to Buy for the Same Price as Beyond Meat * 7 Penny Marijuana Stocks That Are NOT Cheap Stocks The post Best Stocks for 2019: Teladoc Stock Is Here to Stay appeared first on InvestorPlace.
- Simply Wall St.•17 days ago
Here's What We Think About Teladoc Health, Inc.'s (NYSE:TDOC) CEO Pay
In 2009 Jason Gorevic was appointed CEO of Teladoc Health, Inc. (NYSE:TDOC). This analysis aims first to contrast CEO...
- Simply Wall St.•17 days ago
Teladoc Health, Inc. (NYSE:TDOC) Insiders Have Been Selling
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
- Motley Fool•20 days ago
4 Lower-Risk Healthcare Picks for Long-Term Investors
The Healthcare and Wealthcare basket gets investors a diversified and pretty darn safe entry to what can be a very volatile market.
- Business Wire•21 days ago
Robbins Arroyo LLP: Teladoc Health, Inc. (TDOC) Sued for Misleading Investors
Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Teladoc Health (TDOC) has filed a shareholder derivative complaint against the company's officers and directors for breaches of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement, and violations of the Securities Exchange Act of 1934 between March 3, 2016 and the present. Teladoc Health is a virtual care solution company that connects people with medical practitioners.
- Insider Monkey•21 days ago
Here’s What Hedge Funds Think About Teladoc Health, Inc. (TDOC)
Reputable billionaire investors such as Jim Simons, Cliff Asness and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won't accept your savings unless you commit at least $5 million) by pinpointing […]
- GlobeNewswire•23 days ago
Teladoc Health Names Mala Murthy as Chief Financial Officer
Teladoc Health (TDOC), the global leader in virtual care, announced that it has named seasoned financial leader Mala Murthy as chief financial officer. Joining most recently from American Express, Murthy brings an accomplished track record of success across a diverse set of leading public companies and industries. “We are very pleased to welcome Mala to Teladoc Health,” said Jason Gorevic, CEO, Teladoc Health.
- Zacks•29 days ago
Teladoc (TDOC) Up 22% in a Year: Will the Rally Continue?
Teladoc's increasing visits and subscriptions are likely to aid revenue growth. This will further drive its share price.
- Barrons.com•last month
Teladoc Stock Is Rising on a Dose of Optimism for Its Online Therapy Brand
Bank of America Merrill Lynch analyst Allen Lutz highlighted the company’s online therapy brand, BetterHelp, as a potential “crown jewel.”
- Zacks•last month
Why Should You Retain Teladoc (TDOC) in Your Portfolio?
Banking on improving revenues and strategic acquisitions, Teladoc (TDOC) holds great potential to garner benefits for investors.
- Markit•last month
See what the IHS Markit Score report has to say about Teladoc Health Inc.
Teladoc Health Inc NYSE:TDOCView full report here! Summary * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is extremely high for TDOC with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting TDOC. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold TDOC had net inflows of $1.09 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Motley Fool•last month
3 Healthcare Stocks I'd Buy Right Now
Illumina, Teladoc Health, and Vertex Pharmaceuticals enjoy strong competitive advantages and great growth opportunities.
- Simply Wall St.•last month
Is It Too Late To Consider Buying Teladoc Health, Inc. (NYSE:TDOC)?
Teladoc Health, Inc. (NYSE:TDOC), which is in the healthcare services business, and is based in United States, saw a...
- InvestorPlace•last month
5 Healthcare Stocks to Pick Up From the Wreckage
Once loved, healthcare stocks are quickly becoming some of the most hated stocks on the planet. It's easy to understand why. Rising drug and procedure costs have made many healthcare stocks targets for various political pundits and presidential candidates. The growing calls for Medicare-For-All and/or socialized medicine has the potential to hit many healthcare firms right in the pocket. When coupled with the general market sell-off, the fast-moving healthcare sector has been a real downer.But that has only made the sector prime for bargain shopping.Even with calls for increased regulation, the healthcare sector still has great long-term potential. Thanks to rising global demand, aging populations as well as new high-tech and high-margined therapies, there are lots of levers for the sector to pull in order to keep the profits coming. And while some healthcare stocks will be hit hard in the regulation wave (like insurance and pharmacy benefit managers), many will be just fine. This could make the recent declines a tantalizing buy-in point for portfolios.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Stocks to Buy That Could Be Takeover Targets With the long-term in mind, here are five healthcare stocks that are worth picking up from the wreckage. Abiomed (ABMD)Source: Shutterstock There's a good chance that you've never heard of Abiomed (NASDAQ:ABMD). The firm was only added to the S&P 500 about a year ago. But in that time, it has grown immensely in terms of fundamentals and share price.ABMD produces the Impella, which is the world's smallest heart pump. The device is minimally invasive. That's a key selling point for doctors. Open-heart surgery is risky to begin with, but especially so for patients who have suffered some sort of major cardiovascular event. Impella eliminates many of the risks. Meanwhile, the device can be configured in a variety of applications. Because of this, the Impella is quickly becoming the standard of care for doctors in cardiac surgery.As a result, sales of the device continue to surge. For full-year 2018 results, ABMD managed to see a 30% jump in sales and nearly 43% increase in profits based on continued demand for the game-changing device. And yet, the runway is still long for the firm. There's plenty of market share in the U.S. to gain from older heart pump devices and global demand is still in its infancy. Meanwhile, the firm continues to attract plenty of buyout/M&A buzz and would be a wonderful tuck-in deal for many larger device stocks.However, shares of ABMD are about 35% below their all-time highs from last year. And it isn't cheap from a price-to-earnings perspective either. ABMD is a classic growth stock, but the recent dip makes for an interesting buy-in for those willing to hold it over the long term. Teledoc (TDOC)Source: MayApps207 via WikiMedia Saving money and reducing costs is exactly what any pending regulation in the sector will be all about. That's great news for Teledoc (NASDAQ:TDOC). The firm is the largest player in the growing telemedicine field. Here, patients can fire-up their tablets, PCs or smartphones and speak to a physician in real time, get a diagnosis and even send a prescription to their local pharmacy.Health insurers, benefit managers, employers and consumers seem keen on the idea. More employers are adding the service to their benefits package, with more than 40% of the Fortune 500 offering it in their benefits.This has allowed TDOC to experience some very fast growth over the last few years. between 2016 and what its estimated to pull in this year, Teledoc has seen a staggering 64% compound annual growth rate in terms of revenues. Meanwhile, the firm is finally starting to turn those revenues into meaningful and growing profits.And the growth could continue. TDOC has moved into the mental health arena and has been smartly buying smaller rivals to add instant market share. Meanwhile, more companies continue to see the benefits of adding the platform to their Human Resources package. * The 10 Best Stocks for 2019 -- So Far All in all, TDOC is a high growth healthcare stock that is now trading much lower than expected. Amgen (AMGN)Source: Shutterstock As one of biotech and healthcare's elder statesmen, Amgen (NASDAQ:AMGN) has been hit hard over the last year on drug pricing news. Key blockbusters like Enbrel and Neulasta are two of the most prescribed drugs in their categories and mint cash for AMGN. Those blockbusters, as well as others, such as Repatha, blood-cancer drug Kyprolis and bone-density drug Prolia, are the reasons why Amgen has become a dividend and buyback stalwart. Their high prices are also the reason why AMGN is in the crosshairs of lawmakers.Despite that and the drop in AMGN stock, investors may want to consider the firm.For one thing, Amgen continues to dive head first into more advanced cancer and gene therapy drugs. These specialized drugs are naturally higher cost. There's very little that regulation can do for them. With data from Amgen's new cancer therapies crushing the trial, there's a good chance that the firm will have another blockbuster in its arsenal. And we can't forget about its massive pipeline either.In the end, AMGN will be pretty immune from the effects of regulation and will continue to rack up massive cash flows from specialized drugs. That should help pad its now 3.32% dividend for years to come. Stryker Corporation (SYK)Source: Shutterstock Artificial knees, hospital beds and even specialized bone cement … medical device company Stryker (NYSE:SYK) has it all. And that could make it a top healthcare stock contender to snag-up in the recent sector wreckage. SYK has its hands in many pots and that will allow it to handle anything the government throws at it.This is evident by its continued surge in sales and revenues. Last quarter, SYK managed to see a big 8.5% jump in net sales. The key was that divisions featuring more high-tech devices and products, such as orthopedics and neurotechnology, saw big double-digit sales gains. The medical device firm has continued to boost these divisions with smart M&A as well as new innovative internal product launches. That's a good thing as these higher-tech areas are seen as being more insulated to regulation. For Stryker and its shareholders, this could be gold for the long haul.Speaking of that gold, SYK has been sharing the wealth with investors as well. The firm's latest dividend represents a big 11% increase. At the same time, Stryker has been a buyback champ as well -- reducing its share count by about $1 billion last year. * 10 Heavily Shorted Stocks to Sell -- Because the Bears Are Right With a forward P/E of 22, Stryker isn't super cheap, but considering its growth estimates and potential to keep the good times going in the face of regulation, that could seem like a bargain. Bristol-Myers Squibb (BMY)Source: A 4 via Flickr It's not surprising that old-school pharma has been hit hard in recent weeks. But there's nothing particularly old school about Bristol-Myers Squibb (NYSE:BMY). That's because BMY has quickly become the anti-cancer and advanced drug machine.BMY already had top blockbuster cancer-fighter Opdivo, which pulls in more than $2 billion in quarterly revenues for the firm. But thanks to its recent $74 billion out of Celgene (NASDAQ:CELG), Bristol-Meyers will have one of the richest oncology portfolios around. This includes blockbusters Yervoy, Revlimid and Pomalyst which will all now be under its umbrella. This doesn't even include CELG's rich pipeline nor BMY's own advanced cancer-fighting drugs under development.As we said before, specialized cancer drugs are big revenues drivers and given just how advanced they are, the government may have little ability to regulate them. This should help drive revenues and cash flows at Bristol-Meyer's for years to come. And yes, patent expiration for Revlimid is coming down the pike. But under BMY's vast portfolio of drugs, that expiration means less than when it was CELG's chief revenue driver.Yet, BMY trades at a real discount to other big healthcare stocks. For investors, the top and future cancer fighter offers a great long-term play at cheap prices.As of this writing, Aaron Levitt was long AMGN and ABMD. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * The 4 FANG Stocks Won't Be Bitten By Regulation Threats * 10 Stocks to Buy That Could Be Takeover Targets * 4 Big Bank Stocks Rebounding Compare Brokers The post 5 Healthcare Stocks to Pick Up From the Wreckage appeared first on InvestorPlace.
- InvestorPlace•last month
Can the CVS Shift to a Total Healthcare Company Really Work?
Pull up a chart on top healthcare stock CVS Health (NYSE:CVS) and the results aren't pretty. CVS stock has spent the better part of the last five years heading lower. And in fact, CVS has managed to underperform the S&P 500 and the broader healthcare sector by a wide margin. This year alone, CVS stock is down by almost 15%.Source: Mike Mozart via FlickrWhile the part of that has to do with continued fear of pending regulation and government intervention in the healthcare market, the main part continues to be the firm's shift from being simply a pharmacy into something more.CVS has moved into being a total healthcare and wellness provider. Its buyout of insurer Aetna furthers that move. And with management touting some new initiatives at its investor day, CVS stock is fully taking the plunge into being a one-stop shop for Americans.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe question is, will the moves work? CVS's transition continue to be a risky one for investors. However, its new plans may actually pan out. CVS Stock Makes It All About HealthThe healthcare sector is always changing, and for CVS that meant moving beyond simply being a drug and retail outlet. To that end, CVS has bet big bucks on transitioning itself from a strictly healthcare-related retail stock into more of a total package. It bought Caremark, then nursing home/long-term care facility drug distributor Omnicare and now health insurer Aetna. These moves made the firm one of the leading benefits managers in the nation. * 6 Big Dividend Stocks to Buy as Yields Plunge Since then, CVS has started to model its stores into more one-stop shops for all healthcare needs. They stopped selling cigarettes and added about 1,100 MinuteClinics to its stores. These walk-in clinics were designed to allow customers to get flu shots, basic diagnoses and pick-up a prescription for maintenance medications or simple illnesses.And now the firm has continued to transition even further. After positive testing, CVS is prepared to unveil its new CVS HealthHub concept at roughly 1,500 stores. These HealthHub locations will feature expanded health clinic operations, including labs for blood work and health screenings. This could include genetic and other disease testing. Additionally, several locations will be staffed by healthcare specialists such as dietitians and even eye specialists. Finally, CVS plans on adding so-called wellness rooms to these locations. Here, customers can take a yoga class or attend a seminar on say, diabetes care. CVS May Finally Get It RightWhile it may easy to laugh at the idea of taking a yoga class at your local CVS, the new HealthHub concept and roll-out may actually pay some serious benefits for the retail chain.First of all, it gets CVS ahead of online rivals. Amazon (NASDAQ:AMZN) has long hinted that it plans on getting into the pharmacy game and has continued to beef up its presence for generic, over-the-counter medications.Secondly, telemedicine rivals like Teledoc (NSDAQ:TDOC) have surged in popularity with consumers for basic diagnoses. However, CVS has a potential win here with its new roll-out. Health services are one of the few areas untouchable by online means. Additionally, one of the drawbacks to TDOC is that you still need to make a trip to the pharmacy to pick up a prescription. With its MinuteClinics and HealthHubs, consumers are already in a location that can deliver that medication. It's one stop, instead of two.And there is the opportunity to upsell items as well. Consumers can grab other items that come with juicer margins -- beverages, toilet paper, gallons of milk, etc. -- while at the stores. After a vigorous yoga session, it becomes very easy for CVS to prominently display healthier snacks and drinks right outside its wellness rooms.Then there is the health insurance angle to consider. Health insurance companies make money by having their users NOT get sick. For Aetna to boost its profitability, it pays for CVS to keep its members healthy. By offering these wellness programs, checkups and maintenance products, it can keep its members outside hospitals and potentially keep them from needing more intensive care in the first place. Still A Risky BetThe transition for CVS into being a full wellness stock has a ton of potential. It'll allow the firm to fight online rivals, give people a reason to enter its stores and potentially make its insurance operations that much better. The question is, can it work?I think it can, but it won't be a walk in the park. CVS seriously needs to boost its customer service aspects to make the HealthHub concept a reality. In general, CVS is sort of a mixed bag when it comes to customer services. It seems that stores are either very well operated or they are terrible locations with no employees working. It'll take plenty of dollars to make this happen. It hinted at the "billions in new tech" that it'll need to invest to make the concept a reality. Without the CAPEX spend, this could turn into a joke. "Remember when CVS used to offer yoga classes?"That needed spending could be an issue considering that it now has to pay for the $70 billion Aetna acquisition. Already, Omnicare has proved to be a tough pill to swallow. With regulatory pressures mounting, CVS may have a tough time getting the concept up and running effectively.But it's a gamble that investors may want to look at. CVS stock can currently be had for a dirt-cheap forward P/E of about 8 and it does pay a 3.6% dividend yield. At least it's doing something to boost its long-term potential in the face of new rivals.At the time of writing, Aaron Levitt was long AMZN stock. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Stocks to Sell Impacted by the Mexican Tariffs * 6 Big Dividend Stocks to Buy as Yields Plunge * The 10 Biggest Announcements From Apple WWDC 2019 Compare Brokers The post Can the CVS Shift to a Total Healthcare Company Really Work? appeared first on InvestorPlace.
- Zacks•2 months ago
Teladoc (TDOC) Up 0.1% Since Last Earnings Report: Can It Continue?
Teladoc (TDOC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
